Not all Nitro structures are Nitrosamines!
|
|
1
|
559
|
November 2, 2023
|
Developing Structure-Activity Relationships for N-Nitrosamine Activity
|
|
7
|
515
|
October 13, 2023
|
Nitrosamines in Biologics
|
|
1
|
476
|
September 18, 2023
|
Nitrite Detection at Picogram Level, is it possible?
|
|
4
|
730
|
September 14, 2023
|
Identifying the Risk of Formation of Nitrosamines and Other Potentially Mutagenic Impurities during API Manufacture Using In Silico Risk Assessment -Pub
|
|
0
|
1002
|
June 6, 2023
|
A deep dive into historical Ames study data for N-nitrosamine compounds -Pub
|
|
0
|
324
|
September 8, 2023
|
A nitrosamine twist
|
|
0
|
323
|
August 24, 2023
|
Strategies for Assessing Acceptable Intakes for Novel N-Nitrosamines Derived from Active Pharmaceutical Ingredients
|
|
4
|
554
|
August 23, 2023
|
Approaches and Considerations for the Investigation and Synthesis of N‑Nitrosamine Drug Substance-Related Impurities (NDSRIs)
|
|
0
|
503
|
August 23, 2023
|
Maximizing use of existing carcinogenicity data to support AI levels -Pub
|
|
0
|
295
|
July 31, 2023
|
Genotoxicity Assessment using HepaRG Models
|
|
2
|
277
|
July 28, 2023
|
Forced degradation: predicting nitrosamine formation
|
|
8
|
1122
|
July 20, 2023
|
Approaches and Considerations for the Investigation and Synthesis of N-Nitrosamine Drug Substance-Related Impurities (NDSRIs)
|
|
1
|
679
|
May 31, 2023
|
Impact of N‑nitrosamines presence and ARB recall on ARB utilization – results from IQVIA™ Disease Analyzer
|
|
1
|
340
|
May 2, 2023
|
Nuevas inspecciones en busca de Nitrosaminas y Genotóxicos en API no evaluados
|
|
1
|
480
|
May 1, 2023
|
Drawing a line: Where might the cohort of concern end?
|
|
5
|
846
|
April 18, 2023
|
N-Nitrosamines and their precursors in wastewater effluents from selected industries in Spain -Pub
|
|
0
|
243
|
March 29, 2023
|
Computational Prediction of Metabolic α-Carbon Hydroxylation Potential of N-Nitrosamines: Overcoming Data Limitations for Carcinogenicity Assessment
|
|
5
|
735
|
March 23, 2023
|
The Landscape of Small and Drug Substance Related Nitrosamines in Pharmaceuticals
|
|
10
|
1491
|
March 8, 2023
|
U̶p̶c̶o̶m̶i̶n̶g̶ Nitrosamine Special Issue of JPS
|
|
3
|
1595
|
March 7, 2023
|
Solid State Kinetics of Nitrosation Using Native Sources of Nitrite -Pub
|
|
1
|
713
|
March 6, 2023
|
EMA-funded project to predict in-vivo mutagenicity / mutagenicity classification
|
|
6
|
531
|
March 2, 2023
|
Current threat of nitrosamines in pharmaceuticals and scientific strategies for risk mitigation -Pub
|
|
0
|
700
|
February 7, 2023
|
2 years after pushing FDA to analyze Nitrosamines, Valisure cited it for failing to comply with federal law
|
|
3
|
395
|
February 15, 2023
|
Carry over limits for Niitrsoamines
|
|
2
|
547
|
February 12, 2023
|
N-Nitrosamine Formation in Pharmaceutical Solid Drug Products: Experimental Observations -Pub
|
|
0
|
1089
|
February 7, 2023
|
A bioanalytical method for N-nitrosodimethylamine (NDMA) in human samples following ranitidine -Pub
|
|
0
|
402
|
February 7, 2023
|
Nitrosated active pharmaceutical ingredients – lessons learned -Pub
|
|
0
|
648
|
February 7, 2023
|
The impact of N-nitrosamine impurities on clinical drug development -Pub
|
|
1
|
548
|
February 3, 2023
|
Nitrosamine Impurities -Reg Updates Publication
|
|
0
|
665
|
February 1, 2023
|